A population-based matched cohort study examining the mortality and costs of patients with community-onset Clostridium difficile infection identified using emergency department visits and hospital admissions
Few studies have evaluated the mortality or quantified the economic burden of community-onset Clostridium difficile infection (CDI). We estimated the attributable mortality and costs of community-onset CDI. We conducted a population-based matched cohort study. We identified incident subjects with co...
Saved in:
Published in | PloS one Vol. 12; no. 3; p. e0172410 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
03.03.2017
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
ISSN | 1932-6203 1932-6203 |
DOI | 10.1371/journal.pone.0172410 |
Cover
Summary: | Few studies have evaluated the mortality or quantified the economic burden of community-onset Clostridium difficile infection (CDI). We estimated the attributable mortality and costs of community-onset CDI. We conducted a population-based matched cohort study. We identified incident subjects with community-onset CDI using health administrative data (emergency department visits and hospital admissions) in Ontario, Canada between January 1, 2003 and December 31, 2010. We propensity-score matched each infected subject to one uninfected subject and followed subjects in the cohort until December 31, 2011. We evaluated all-cause mortality and costs (unadjusted and adjusted for survival) from the healthcare payer perspective (2014 Canadian dollars). During our study period, we identified 7,950 infected subjects. The mean age was 63.5 years (standard deviation = 22.0), 62.7% were female, and 45.0% were very high users of the healthcare system. The relative risk for 30-day, 180-day, and 1-year mortality were 7.32 (95% confidence interval [CI], 5.94-9.02), 3.55 (95%CI, 3.17-3.97), and 2.59 (95%CI, 2.37-2.83), respectively. Mean attributable cumulative 30-day, 180-day, and 1-year costs (unadjusted for survival) were $7,434 (95%CI, $7,122-$7,762), $12,517 (95%CI, $11,687-$13,366), and $13,217 (95%CI, $12,062-$14,388). Mean attributable cumulative 1-, 2-, and 3-year costs (adjusted for survival) were $10,700 (95%CI, $9,811-$11,645), $13,312 (95%CI, $12,024-$14,682), and $15,812 (95%CI, $14,159-$17,571). Infected subjects had considerably higher risk of all-cause mortality and costs compared with uninfected subjects. This study provides insight on an understudied patient group. Our study findings will facilitate assessment of interventions to prevent community-onset CDI. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: Natasha Nanwa received stipend support throughout her PhD graduate work from the University of Toronto, Pfizer Canada, the Ontario Graduate Scholarship program, and a Canadian Institutes of Health Research (CIHR) operating grant which funded this study. Jeffrey C. Kwong is supported by a CIHR New Investigator Award and a Clinician Scientist Award from the University of Toronto’s Department of Family and Community Medicine. Peter C. Austin is supported in part by a Career Investigator Award from the Heart and Stroke Foundation of Canada. Nick Daneman is supported by a CIHR Clinician Scientist Award. The other authors declare no competing interests. The University of Toronto, Pfizer Canada, the Ontario Graduate Scholarship program, the Heart and Stroke Foundation, and CIHR did not participate in: study design/concept; data acquisition, analysis, or interpretation; or manuscript drafting or review. There are restrictions on sharing data from our study as public deposition of the individual-level data used in this study is not legally permitted due to provincial privacy legislation (Personal Health Information Protection Act) and the contractual obligations of the data sharing agreements between the Institute for Clinical Evaluative Sciences (ICES) and the data providers. Please refer to the following link for more information: http://www.ices.on.ca/Data-and-Privacy/Privacy%20at%20ICES. Conceptualization: NN JCK BS MK ND HL PCA AG LCR SMC.Data curation: NN HL.Formal analysis: NN.Funding acquisition: NN JCK BS MK ND PCA.Investigation: NN.Methodology: NN JCK BS MK ND HL PCA AG LCR SMC.Project administration: NN JCK BS MK.Resources: JCK BS MK.Software: NN HL.Supervision: JCK BS MK.Validation: NN.Visualization: NN.Writing – original draft: NN JCK BS.Writing – review & editing: NN JCK BS MK ND HL PCA AG LCR SMC. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0172410 |